Version 2 2024-06-05, 04:09Version 2 2024-06-05, 04:09
Version 1 2015-08-25, 14:16Version 1 2015-08-25, 14:16
journal contribution
posted on 2024-06-05, 04:09authored byTJ Kidd, KA Ramsay, S Vidmar, JB Carlin, SC Bell, CE Wainwright, K Grimwood, PW Francis, C Dakin, J Cheney, N George, CF Robertson, Marj MoodieMarj Moodie, R Carzino, Rob CarterRob Carter, B Whitehead, J Hunter, CA Byrnes, HA Tiddens, K Graniel, K Gerbrands, L Mott
BACKGROUND: We describe Pseudomonas aeruginosa acquisitions in children with cystic fibrosis (CF) aged ≤5-years, eradication treatment efficacy, and genotypic relationships between upper and lower airway isolates and strains from non-CF sources. METHODS: Of 168 CF children aged ≤5-years in a bronchoalveolar lavage (BAL)-directed therapy trial, 155 had detailed microbiological results. Overall, 201/271 (74%) P. aeruginosa isolates from BAL and oropharyngeal cultures were available for genotyping, including those collected before and after eradication therapy. RESULTS: Eighty-two (53%) subjects acquired P. aeruginosa, of which most were unique strains. Initial eradication success rate was 90%, but 36 (44%) reacquired P. aeruginosa, with genotypic substitutions more common in BAL (12/14) than oropharyngeal (3/11) cultures. Moreover, oropharyngeal cultures did not predict BAL genotypes reliably. CONCLUSIONS: CF children acquire environmental P. aeruginosa strains frequently. However, discordance between BAL and oropharyngeal strains raises questions over upper airway reservoirs and how to best determine eradication in non-expectorating children.